Akso Health
Valuation each multiple against its own 5-year range
Vs. peers Medical Distribution
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Akso Health (AHG) | 1.08B | -42.00 | 5.97 | 0.00% |
| McKesson (MCK) | 123.47B | 27.48 | -31.23 | 0.32% |
| Cencora (COR) | 64.71B | 18.89 | 17.58 | 0.71% |
| Cardinal Health (CAH) | 63.06B | 35.29 | -20.84 | 0.75% |
| Henry Schein (HSIC) | 9.23B | 22.88 | 2.92 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 2.2% below Morningstar's fair value estimate.
Fair value
Akso Health Group is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 4% discount to our quantitative fair value estimate of $1.29 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The firm's balance sheet increases our fair value estimate. Low leverage mitigates financial risk, potentially boosting a firm's value. Reflecting the firm's leverage is its current ratio of 21.8, which lies in the top 10% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are cheap.
Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's cash flow yield of -0.1%, a core component of profitability, ranks in the bottom 30% globally. At the current valuation, the yield of cash flow from operations to investors looks paltry. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.
Economic moat
The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Akso Health discussion 0 comments